Bosutinib (Bosulif)

General information

Class/mechanism: Third-generation tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Also inhibits kinases in the Src family, including Src, Lyn, and Hck. Active against many imatinib-resistant mutations (16 of 18 imatinib-resistant forms of Bcr-Abl in murine myeloid cell lines), but not active against the T315I and V299L mutations.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the package insert.

Diseases for which it is used

• Chronic myelogenous leukemia (CML)
• Ph+ B-cell ALL

Patient drug information

• Bosutinib (Bosulif) package insert
• Bosutinib (Bosulif) patient drug information (Chemocare)
• Bosutinib (Bosulif) patient drug information (UpToDate)

History of changes in FDA indication

• 9/4/2012: Initial approval for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. (Based on Study 200)
• 12/19/2017: Accelerated approval for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). (Based on BFORE)
  • 5/14/2021: Converted to regular approval. (Based on BFORE)

History of changes in EMA indication

• 3/27/2013: Initial authorization

Also known as

• Code name: SKI-606
• Brand name: Bosulif